The generation of genetically modified animals has been suggested as an alternative for the production of recombinant drugs for human or animal use, however it is also an alternative for the generation of more disease resistant or more productive animals. Currently there are several alternatives to generate genetically modified animals, but still inefficient when applied in animals of zootechnical production. This project was part of Embrapa's project network entitled "Animal biotechnology in the selection, multiplication, biological safety, exchange and dissemination of genetic resources in different production systems aimed at the competitiveness of national livestock" and dedicated to the genetic manipulation of cells and Mammalian gametes for the production of recombinant factors or for the production of genetically modified embryos and animals by different approaches. Initial knowledge was generated with potential to contribute to the understanding of mechanisms involved in the production of genetically modified cells and embryos. It was found that cloned embryos reconstructed with cells genetically modified with the green fluorescent protein (GFP) gene develop more efficiently when treated with 50 nM of tricostatin, a histone deacetylase inhibitor. This practice may potentially favor the improvement in the production of genetically modified bovine embryos for the purpose of producing biopharmaceuticals or genetically engineered animals. Another result of this project was the expression of the GDF9 and BMP15 factors granulosa cell genetically modified by lipofection, which can potentially be used for the improvement of the in vitro production system of bovine embryos. The processes and practices generated can contribute to the production of genetically modified embryos and animals.